Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: Patient-reported outcomes from a Phase II randomized controlled trial

Journal of Dermatological Treatment

Volumn 18, Issue 1, 2007, Pages 25-31

  Shikiar, Richard ^a   Heffernan, Michael ^b   Langley, Richard G ^c   Willian, Mary K ^d   Okun, Martin M ^d   Revicki, Dennis A ^e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

^d ABBOTT LABORATORIES   (United States)

^e UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Adalimumab; Health related quality of life; Patient reported outcomes; Psoriasis; Randomized controlled trial; Tumor necrosis factor antagonists

Indexed keywords

ADALIMUMAB;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; EMOTION; FEMALE; HEALTH SURVEY; HUMAN; INSTRUMENTATION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; SOCIAL ASPECT; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CANADA; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; UNITED STATES;

EID: 33947106908     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601121060     Document Type: Article

References (36)

1. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281-5.
2. Callen J, Krueger GG, Lebwohl M, McBurney EI, Mease P, Menter A, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol. 2003;49:897-9.
3. De Arruda LH, De Moraes AP. The impact of psoriasis on quality of life. Br J Dermatol. 2001;144:33-6.
4. Finlay AY. Quality of life assessments in dermatology. Semin Cutan Med Surg. 1998;17:291-6.
5. Rapp SR, Cottrell CA, Leary MR. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol. 2001;145:610-16.
6. Wahl A. The impact of psoriasis on psychosocial life domains. A review. Scand J Caring Sci. 1997;11:243-9.
7. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512-18.
8. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: Results of 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137:280-4.
9. Fleischer AB Jr, Feldman SR, Rapp SR, Reboussin DM, Exum ML, Clark AR, et al. Disease severity measures in a population of psoriasis patients: The symptoms of psoriasis correlate wi4h self-administered psoriasis area severity index scores. J Invest Dermatol. 1996;107:26-9.
10. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes. 2006;4:35. Available at: www.hqlo.com/content/4/1/35. Open access October 3, 2006.
11. Rapp SR, Feldman SR, Exum L, Fleischer Jr AB, Reboussin A. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;4:401-7.
12. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004;150:317-26.
13. Finlay AY, Salek MS, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology. 2003;206:307-15.
14. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA. 2003;290:3073-80.
15. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-32; discussion 1632.
16. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
17. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol. 2004;3:27-38.
18. Tyring S, Gottleib A, Papp K, Gordon K, Leornardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue and depression in psoriasis: Double-blind, placebo-controlled randomized phase III trial. Lancet. 2006;367:29-35.
19. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol. 2005;153:486-97.
20. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol. 2003;21:241-8.
21. Van de Putte LBA, Salfeld J, Kaymakcalan Z. Adalimumab. In: Moreland LW, Emery P, editors. TNFa-inhibition in the treatment of rheumatoid arthritis. London: Martin Dunitz; 2003. p. 71-93.
22. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al., Clinical response to adalimumab treatment in moderate to severe psoriasis patients: Double-blind, randomized clinical trial and open-label extension study. J Am Acad Dermatol. 2006;55:598-606.
23. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210-16.
24. Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: Clinical validity, reliability and sensitivity to change of the DLQI. The Cavide Research Group. Br J Dermatol. 1999;141:698-702.
25. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9:169-80.
26. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The Validity and Responsiveness of Three Quality of Life Measures in the Assessment of Psoriasis Patients: Results of a Phase II Study. Health Qual Life Outcomes. 2006;4:71 (27 September 2006). Open access available at: www.hqlo.com.
27. Ware JE, Kosinski MK, Keller SD. SF-36 Physical and Mental Health Summary Scales: A user's manual. Boston: The Health Institute, New England Medical Center; 1994.
28. Wahl A, Loge JH, Wiklund I, Hanestad BR. The burden of psoriasis: A study concerning health-related quality of life among Norwegian adult patients with psoriasis compared with general population norms. J Am Acad Dermatol. 2000;43:803-8.
29. EuroQOL Group: EuroQOL - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
30. Kind P. The EuroQOL Instrument: An index of health-related quality of life. In: Quality of life and pharmacoeconomics in clinical trials. 2nd ed. In: Spilker B, editor. Philadelphia: Lippincott-Raven Publishers; 1996. p. 191-201.
31. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index. Br J Dermatol. 2002;147:50 (abstract).
32. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861-7.
33. Gibson RS, Sazawal S, Peerson JM. Design and quality control issues related to dietary assessment, randomized controlled trials and meta-analysis of field-based studies in developing countries. J Nutr. 2003;133:1569S-73S.
34. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. 2000;43:1478-87.
35. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: Results of a Phase II study. Health Qual Life Outcomes. 2006;4:71. Open access available at: www.hqlo.com
36. Simon GE, Revicki DA, Grothaus L, von Korff M. SF-36 summary scores: Are physical and mental health truly distinct? Medical Care. 1998;36:567-72.